Clinical Trial Update: Nintedanib in Patients With Advanced Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of nintedanib in advanced esophagogastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma
• Esophagogastric Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophagogastric Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-01-25